Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

ConditionsMetastatic Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Stage II Non Small Cell Lung Cancer Stage III Small-cell Lung Cancer Non-small Cell Lung Cancer Stage I

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorAIO-Studien-gGmbH

About this trial

Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany

Eligibility criteria

Qualifiers

Age ≥ 18 years

Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments

Confirmed non-small cell lung cancer (NSCLC)

Informed consent no later than four weeks after start of first-line systemic treatment or no later than four weeks after diagnosis for patients receiving "best supportive care only"

Disqualifiers

None

Trial design

Treatments tested in this trial

data collection

Treatment groups

12,400 Participants

are divided into 5 treatment groups

Sponsors and collaborators

AIO-Studien-gGmbH

Lead sponsor

AstraZeneca

Collaborator

Celgene Corporation

Collaborator

Merck Sharp & Dohme LLC

Collaborator

Novartis Pharmaceuticals

Collaborator

Pfizer

Collaborator

Boehringer Ingelheim

Collaborator

Bristol-Myers Squibb

Collaborator

iOMEDICO AG

Collaborator

Eli Lilly and Company

Collaborator

Roche Pharma AG

Collaborator

Takeda

Collaborator

Amgen

Collaborator

Janssen-Cilag G.m.b.H

Collaborator

GlaxoSmithKline

Collaborator

Daiichi Sankyo

Collaborator

Regeneron Pharmaceuticals

Collaborator

Gilead Sciences

Collaborator

Source ClinicalTrials.gov